Abstract:Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis and a high degree of relapse seen in patients. Overexpression of FMS-like tyrosine kinase 3 (FLT3) is associated with up to 70% of AML patients. Wild-type FLT3 induces proliferation and inhibits apoptosis in AML cells, while uncontrolled proliferation of FLT3 kinase activity is also associated with FLT3 mutations. Therefore, inhibiting FLT3 activity is a promising AML therapy. Flavonoids are a group of phytochemicals that can target protein kinases, suggesting their potential antitumor activities. In this study, several plant-derived flavonoids have been identified with FLT3 inhibitory activity. Among these compounds, compound 40 (5,7,4′-trihydroxy-6-methoxyflavone) exhibited the most potent inhibition against not only FLT3 (IC50 = 0.44 μM) but also FLT3-D835Y and FLT3-ITD mutants (IC50 = 0.23 and 0.39 μM, respectively). The critical interactions between the FLT3 binding site and the compounds were identified by performing a structure–activity relationship analysis. Furthermore, the results of cellular assays revealed that compounds 28, 31, 32, and 40 exhibited significant cytotoxicity against two human AML cell lines (MOLM-13 and MV-4-11), and compounds 31, 32, and 40 resulted in cell apoptosis and G0/G1 cell cycle arrest. Collectively, these flavonoids have the potential to be further optimized as FLT3 inhibitors and provide valuable chemical information for the development of new AML drugs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jnatprod.0c00589?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jnatprod.0c00589</a>.Inhibition activity of in-house flavonoid library against FLT3; validation of docking protocol; inhibition activity analysis of flavonoid subclasses; interaction analysis between active and inactive compounds; interaction analysis of compounds 28, 31, 32, and 40; interaction analysis of flavonols, chalcones, flavanones, and prenylflavanones in the FLT3 binding site; cell apoptosis effect on the cell cycle with compound 32 and 40 treatment (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c00589/suppl_file/np0c00589_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, Synthesis, and Evaluation of Pyrido.[3,4-B]pyrazin-2(1h)-one Derivatives As Potent FLT3 Inhibitors

Design, synthesis, and evaluation of pyrido.[3,4–b]pyrazin-2(1 H )-one derivatives as potent FLT3 inhibitors

Recent advances in FLT3 inhibitors for acute myeloid leukemia.

Design, synthesis, and biological evaluation of a series of indolone derivatives as novel FLT3 inhibitors for the treatment of acute myeloid leukemia

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1H-Pyrazole-3-Carboxamide Derivatives and Their Potent Activity Against Acute Myeloid Leukemia (AML)

Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine Derivatives As Type-II Inhibitors of FLT3 Selective Against C-Kit

Discovery of the Selective and Efficacious Inhibitors of FLT3 Mutations

Identification of 2-Aminopyrimidine Derivatives As FLT3 Kinase Inhibitors with High Selectivity over C-Kit.

Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia.

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Combining Structure- and Property-Based Optimization to Identify Selective FLT3-ITD Inhibitors with Good Antitumor Efficacy in AML Cell Inoculated Mouse Xenograft Model.

Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations

Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia

Rational Design of 4-((6-phenoxypyrimidin-4-yl)amino)-n-(4-(piperazin-1-yl)phenyl)-1h-pyrazole-3-carboxamide (LT-540-717) As Orally Bioavailable FLT3 Inhibitor

Structure-activity Relationship Studies of Pyrazolo[3,4-D]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity Against Acute Myeloid Leukemia in Vitro and in Vivo.

Discovery and structure − activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors